Detalhe da pesquisa
1.
Superior outcomes and high-risk features with carfilzomib, lenalidomide, and dexamethasone combination therapy for patients with relapsed and refractory multiple myeloma: Results of the multicenter KMMWP2201 study.
Haematologica
; 2024 Jun 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-38841794
2.
Relapse with plasmacytoma after upfront autologous stem cell transplantation in multiple myeloma.
Ann Hematol
; 101(6): 1217-1226, 2022 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-35445844
3.
Early transplantation-related mortality after allogeneic hematopoietic cell transplantation in patients with acute leukemia.
BMC Cancer
; 21(1): 177, 2021 Feb 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-33602150
4.
Carfilzomib in addition to lenalidomide and dexamethasone in Asian patients with RRMM outside of a clinical trial.
Ann Hematol
; 100(8): 2051-2059, 2021 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-33447888
5.
Incidence, prevalence, mortality, and causes of death in Waldenström macroglobulinemia: a nationwide, population-based cohort study.
BMC Cancer
; 20(1): 623, 2020 Jul 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-32620091
6.
Endothelial activation and stress index (EASIX) is a reliable predictor for overall survival in patients with multiple myeloma.
BMC Cancer
; 20(1): 803, 2020 Aug 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-32831058
7.
Clinical features and treatment outcomes of limited-stage mantle cell lymphoma: Consortium for Improving Survival of Lymphoma report.
Ann Hematol
; 99(2): 223-228, 2020 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-31853704
8.
The effectiveness and safety of lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma in real-world clinical practice: a study of the Korean Multiple Myeloma Working Party (KMMWP-151 study).
Ann Hematol
; 99(2): 309-319, 2020 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-31872360
9.
Pomalidomide, cyclophosphamide, and dexamethasone for elderly patients with relapsed and refractory multiple myeloma: A study of the Korean Multiple Myeloma Working Party (KMMWP-164 study).
Am J Hematol
; 95(4): 413-421, 2020 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-31919872
10.
Treatment with intravenous busulfan, melphalan, and etoposide followed by autologous stem cell transplantation in patients with non-Hodgkin's lymphoma: a multicenter study from the consortium for improving survival of lymphoma.
Transpl Int
; 33(10): 1211-1219, 2020 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-32479690
11.
The effects of erythropoiesis-stimulating agents on the management of chemotherapy-induced anemia and tumor growth in diffuse large B-cell lymphoma patients.
Int J Cancer
; 145(9): 2459-2467, 2019 11 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30973963
12.
Ruxolitinib shows activity against Hodgkin lymphoma but not primary mediastinal large B-cell lymphoma.
BMC Cancer
; 19(1): 1080, 2019 Nov 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-31707975
13.
Echinochrome A Promotes Ex Vivo Expansion of Peripheral Blood-Derived CD34+ Cells, Potentially through Downregulation of ROS Production and Activation of the Src-Lyn-p110δ Pathway.
Mar Drugs
; 17(9)2019 Sep 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-31505769
14.
Phase 2 Study of an Intravenous Busulfan and Melphalan Conditioning Regimen for Autologous Stem Cell Transplantation in Patients with Multiple Myeloma (KMM150).
Biol Blood Marrow Transplant
; 24(5): 923-929, 2018 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-29339269
15.
Bendamustine plus rituximab for relapsed or refractory diffuse large B cell lymphoma: a multicenter retrospective analysis.
Ann Hematol
; 97(8): 1437-1443, 2018 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-29619501
16.
Response to hypomethylating agents improves long-term outcomes for lower-risk patients with myelodysplastic syndrome in case-matched cohorts.
Ann Hematol
; 97(12): 2309-2317, 2018 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-30073392
17.
The Derived Neutrophil-to-Lymphocyte Ratio Is an Independent Prognostic Factor in Transplantation Ineligible Patients with Multiple Myeloma.
Acta Haematol
; 140(3): 146-156, 2018.
Artigo
em Inglês
| MEDLINE | ID: mdl-30253397
18.
Clinical trial participation improves survival outcomes by increasing availability of new therapeutic agents in multiple myeloma.
Br J Haematol
; 196(4): 1117-1120, 2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-34671972
19.
Nilotinib combined with multiagent chemotherapy for newly diagnosed Philadelphia-positive acute lymphoblastic leukemia.
Blood
; 126(6): 746-56, 2015 Aug 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-26065651
20.
Correction to: Relapse with plasmacytoma after upfront autologous stem cell transplantation in multiple myeloma.
Ann Hematol
; 101(7): 1625, 2022 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-35604472